Navigation Links
Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
Date:4/10/2008

ther platinum therapies."

ProLindac is currently in a Phase 2 dose-escalating monotherapy trial in recurrent ovarian cancer. Access is currently in the process of planning additional ProLindac clinical trials that will include combination therapy trials in one or more solid tumor types.

About Access:

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; Prodrax(R), a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to overcome drug resistance. Access is also developing Phenylbutyrate ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our ability to close the financing transaction, early results from our clinical trial, Access' plans to continue and initiate clinical trials, the value of its products in the market, its ability to achieve cli
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. New Legislation Would Expedite Medicare Patient Access to Physical Therapy
2. SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
3. Medicare Advantage Plans Have New, Better Way to Access CMS Data
4. Stryker to Provide Webcast and Telephone Access to Annual Shareholder Meeting
5. Increasing access to antiretroviral drugs would drastically cut AIDS deaths in South Africa
6. Open Biosystems Open Access RNAi Program Continues to Gain Momentum Worldwide
7. Toms of Maine Helps Increase Access to Dental Care
8. Medicare Bidding Program for Durable Medical Equipment May Harm Small Businesses and Decrease Patient Access to Care, Say 137 Members of Congress
9. Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
10. Governor Rendell Says Pennsylvania is One Step Closer to Providing Access to Health Care for Pennsylvanias Uninsured
11. Country Music Star Troy Gentry Partners With National Non-Profit Patient Advocate Foundation to Spread the Message About Challenges to Healthcare Access for Insured and Uninsured Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... The Hydration ... allopathic medicine, opens its second location this week at 31542 S. Coast Hwy, ... feet of lounge space for patients to relax while receiving safe and effective ...
(Date:9/2/2015)... Burnsville, MN (PRWEB) , ... September 02, 2015 , ... ... forward to it; others dread it. However, few are prepared to face the academic ... once school starts. Our schools haven’t prepared them since schools don’t teach students how ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the upper extremity surgical market, announced today that more than 600 successful patient ... in the hand. Plus, nearly 70 of these procedures have been on ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a nationally recognized ... Overdose Awareness Day. The goal is to provide people information regarding drugs and ... they may get help. , Lakeview Health will be publishing information ...
(Date:9/2/2015)... PA (PRWEB) , ... September 02, 2015 , ... Pentec ... prestigious 2015 Inc. 5000 List for an impressive sixth consecutive year. Less than 5 ... with only twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate ...
Breaking Medicine News(10 mins):Health News:The Hydration Room Opens New Location In Laguna Beach, California 2Health News:The Hydration Room Opens New Location In Laguna Beach, California 3Health News:The Hydration Room Opens New Location In Laguna Beach, California 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... Tenn., Jan. 13 The National Eczema Association,(NEA) awarded ... Lotion. , The NEA Seal ... Education (EASE) program, which is intended to improve the,quality ... eczema and sensitive,skin. , "These ...
... now open for a more rewarding challenge , ... Jenkintown, PA (PRWEB) January 13, 2009 ... resolutions and according to USA.gov, losing weight and getting fit are among the ... many of those eager to fulfill their vows is to lace up their ...
... to meet their customers, product needs quickly and efficiently, Nationwide Medical/Surgical ... 2009-2010 season beginning in August. , ... (Vocus) January ... the Flu Vaccine for the 2009-2010 flu season. ...
... persistence to seek out the best treatment options available ... leg today. Bill,s proactive efforts led him to revolutionary ... Methodist Hospital, in Columbus, Ohio, where a team of ... During the minimally invasive procedure, they also found and ...
... announces the launch of their new website www.GlaceComplete.com . ... to Glenwood Systems and the company,s turbo-charged practice management/billing system GlaceComplete ... information. , ... Waterbury, CT (PRWEB) January Monday 12, ...
... of the 21,000 Americans who die each year of ... likely cause. So, the American Association of ... Cancer Survivors Against Radon (CanSAR) with a ... those who never smoked. Those making the connection, along ...
Cached Medicine News:Health News:National Eczema Association Anoints Theraplex Child-Friendly Eczema Products with Seal of Acceptance 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 2Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 3Health News:The Breast Cancer 3-Day Challenges Americans to Get Out of the New Year's Resolution Rut 4Health News:Nationwide Medical/Surgical Announces They Will Carry Flu Vaccine 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 2Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 3Health News:Irishman with Peripheral Arterial Disease (P.A.D.) Finds Leg-, Life-Saving Treatment In Columbus, Ohio 4Health News:Glenwood Systems, LLC Launches New Website -- GlaceComplete.com 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 2Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 3Health News:Program to Identify Likely Victims of Radon-Related Lung Cancer; Survivors Commit to Risk Reduction Despite Failed Government Policy 4
(Date:9/2/2015)... and MENLO PARK, Calif. , ... (OTCQX: DMPI) ("DelMar" and the "Company"), a ... of new cancer therapies, today announced that it ... of the Mechanisms and Cytotoxic Activity of Dianhydrogalactitol ... Wild-type and Mutant p53," at the American ...
(Date:9/2/2015)... Sept. 2, 2015 CytoSorbents Corporation (NASDAQ: ... CytoSorb ® blood purification technology to reduce deadly ... that CEO Dr. Phillip Chan , MD, PhD, ... Investment Conference (sponsored by H.C. Wainwright & ... New York City.  Currently, the management ...
(Date:9/2/2015)... Ascletis announced today the completion of a US$35 million ... C-Bridge Capital, joined by Tasly Pharmaceutical and ... Company before financing was US$300 million. The ... Ascletis, pipeline, strengthen global development capabilities and enhance GMP ... investors, Ascletis is now entering an exciting new era. ...
Breaking Medicine Technology:DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 2DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 3DelMar Pharmaceuticals Announces Expansion of VAL-083 Development Program to Include Ovarian Cancer 4CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 2CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 3CytoSorbents to Present at the 2015 Rodman & Renshaw Annual Global Investment Conference 4Ascletis Secures US$35 Million Financing 2Ascletis Secures US$35 Million Financing 3
... VIENNA, Va., June 20, 2007 /PRNewswire/ ... announced the successful completion of,pharmacokinetic and ... hormone, long-acting interferon beta and,long-acting erythropoietin. ... demonstrated superb durability of the long-acting,proteins, ...
... /PRNewswire-FirstCall/ -- Amylin,Pharmaceuticals, Inc. today announced that ... injection and,SYMLIN(R) (pramlintide acetate) injection, and its ... Diabetes Association's,(ADA) 67th Annual Scientific Sessions being ... 26. The company will also host an ...
Cached Medicine Technology:Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 2Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 3Modigene Announces Successful Completion of Pharmacokinetic &,Pharmacodynamic Pre-Clinical Experiments for Proprietary,Long-Acting Human Growth Hormone, Long-acting Interferon Beta and,Long-acting Erythropoietin 4Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 2Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 3Amylin Pharmaceuticals to Present New Data from Broad Diabetes and,Obesity Programs at ADA 2007 4
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: